Clinical trials referenced in this document:
Documents that mention this clinical trial
Evaluating the Safety and Efficacy of Sodium-Glucose Co-transporter 2 Inhibitors in Subjects with Prediabetes: A Protocol for a Randomized Controlled Trial
https://doi.org/10.1007/s13300-024-01560-3
Funding for this research was provided by:
Key Technologies Research and Development Program (2022YFC2702600)
National Key Clinical Specialty Discipline Construction Program of China
Article History
Received: 15 January 2024
Accepted: 27 February 2024
First Online: 18 March 2024
Declarations
:
: Xiaxuan Zhu, Li Xia, Deshan Yin, Jin Yang, and Rui Wei declare that they have no competing interests.
: Approval to conduct the study was gained from the Peking University Third Hospital Medical Science Research Ethics Committee (reference number CN-032), with the Approval Number IRB00006761-M2022520. Prior to any study-related activities, all potential participants will be recruited by the researchers and thoroughly informed about the study’s objectives, procedures, potential risks, and benefits. Written informed consent will be obtained from all participants, ensuring their voluntary participation and understanding of their rights to withdraw from the study at any time without any consequences. This consent process is designed to protect the participants’ autonomy and confidentiality, with all data collected being anonymized to ensure privacy.